



## Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 12, 2023

CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 22<sup>nd</sup> Annual Needham Virtual Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.

Format: Virtual Presentation and 1x1 Investor Meetings  
Virtual Presentation: April 19 from 12:45 - 1:25 pm ET in Track 1

The presentations will be webcast live and archived for 30 days in the Investor Relations section of Immuneering's website at [Events & Presentations | Immuneering Corporation](#).

### About Immuneering Corporation

Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering's lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company's development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit [www.immuneering.com](http://www.immuneering.com).

#### Media Contact:

Gina Nugent  
Nugent Communications  
617-460-3579  
[gina@nugentcommunications.com](mailto:gina@nugentcommunications.com)

#### Investor Contacts:

Laurence Watts  
Gilmartin Group  
619-916-7620  
[laurence@gilmartinir.com](mailto:laurence@gilmartinir.com)

or

Kiki Patel, PharmD  
Gilmartin Group  
332-895-3225  
[kiki@gilmartinir.com](mailto:kiki@gilmartinir.com)